Venetoclax with Azacytidine Improved Overall Survival for Patients with AML


Genentech recently announced their phase III study resulted in improved overall survival and composite complete remission rates for patients with previously untreated acute myeloid leukemia.

Source: CancerNetworkCategory: Cancer & Oncology Authors: Source Type: news

Related Links:

Basel, 23 March 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the phase III VIALE-A study met its dual primary endpoints of overall survival and composite complete remission rate (CR + CRi). Venclexta ®/Venclyxto® (venetoclax) in combination with azacitidine, a hypomethylating agent, showed a statistically significant improvement in overall survival in people with previously untreated acute myeloid leukaemia (AML) who were ineligible for intensive induction chemotherapy, compared to azacitidine alone. Safety for Venclexta/Venclyxto plus azacitidine appeared consistent with the known safety profile …

Fight Aging! publishes news and commentary relevant to the goal of ending all age-related disease, to be achieved by bringing the mechanisms of aging under the control of modern medicine. This weekly newsletter is sent to thousands of interested subscribers. To subscribe or unsubscribe from the newsletter,
please visit:

Longevity Industry Consulting Services

Reason, the founder of Fight Aging! and Repair Biotechnologies, offers strategic consulting services to investors, entrepreneurs, and others interested in the longevity industry and its complexities. To find out m…

Source: Fight Aging!Category: Research Authors: Tags: Newsletters Source Type: blogs

Conclusions: These PPY data, showing shorter durations of hospitalization and similar use of supportive care with CPX-351 versus 7 + 3, suggest CPX-351 is not associated with increased HRU in older patients with newly diagnosed high-risk/secondary AML.
PMID: 32188326 [PubMed – as supplied by publisher]

Cells become senescent in response to a variety of circumstances. The vast majority are cases of replicative senescence, somatic cells reaching the Hayflick limit. Cell damage and toxic environments also produce senescence, and senescent cells are also created as a part of the wound healing process. A senescent cell ceases replication and begins to secrete inflammatory and pro-growth signals, altering the nearby extracellular matrix and behavior of surrounding cells – even encouraging them to become senescent as well.

Near all senescent cells last a short time only, as they self-destruct or are removed by the immune…

Source: Fight Aging!Category: Research Authors: Tags: Medicine, Biotech, Research Source Type: blogs

(Impact Journals LLC) Oncotarget Volume 11, Issue 11 reported that in this preclinical study, we characterized the binding affinity and selectivity of quizartinib, a small-molecule inhibitor of FLT3, and AC886, the active metabolite of quizartinib, compared with those of other FLT3 inhibitors.Dr. Takeshi Isoyama from Daiichi Sankyo Co., Ltd. said, ” FMS like tyrosine kinase 3 (FLT3) is a receptor tyrosine kinase expressed by acute myeloid leukemia (AML) cells in 70% to 90% of patients. “

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, aggressive malignancy derived from the plasmacytoid dendritic cell that commonly involves the skin. Cutaneous involvement is often the initial presentation, with deep purple or red-brown macules, plaques, or tumors. As such, dermatologists may be the first to see these patients and, in addition to oncologists, should be familiar with its presentation to facilitate early diagnosis, helping to distinguish it from acute myelogenous leukemia cutis.

Publication date: Available online 18 March 2020Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Claire Comerford, Sarah Ni Mhaolcatha, Brian Hayes, Vitaliy Mykytiv

Authors: Qin Y, Wang Y, Liu D
It has been reported that Kindlin-3 expression is closely associated with progression ofmany cancers and microRNA (miRNA) processing. However, the effects and its precisemechanisms of Kindlin-3 in acute myeloid leukemia (AML) have not been wellclarified. Our study aimed to explore the interaction between Kindlin-3 and miR-4792in AML. In our study, we found that the expression of Kindlin-3 was dramaticallyincreased in AML samples and cell lines, and the miR-4792 level was significantlydown-regulated. Interestingly, the low miR-4792 level was closely associated withup-regulated …

Source: Oncology ResearchCategory: Cancer & Oncology Tags: Oncol Res Source Type: research

Fifty ‐two patients with relapsed/refractory acute myeloid leukemia (AML) were treated with clofarabine, cytarabine, and mitoxantrone. The overall response rate (ORR) was 90.4% (complete remission, CR: 69.2%; CR with incomplete hematological recovery, CRi: 21.2%), with 22 CR/CRi patients undergoing allo geneic hematopoietic stem cell transplantation (allo‐HSCT), while in CR; resulting in a 2‐year OS of 84.3% in CR patients and 90% in patients receiving allo‐HSCT. Clofarabine, cytarabine, and mitoxantrone resulted in high ORR and was safe in refractory/relapsed AML. AbstractClofarabine is active in refractory/relaps…

Source: Cancer MedicineCategory: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research

Authors: Shallis RM, Podoltsev NA, Gowda L, Zeidan AM, Gore SD
Introduction: The myelodysplastic syndromes (MDS) vary in their risk of disease progression; progression includes increasingly severe bone marrow failure, reclassification as acute myeloid leukemia (AML), and death. Prognostic tools guide recommendations for allogeneic stem cell transplantation (alloSCT), the only curative option. AlloSCT is typically reserved for patients with higher-risk MDS as defined by existing prognostic tools, although additional clinical and biological factors in lower-risk patients may influence this dogma.Areas covere…

Source link